Korsana Biosciences, Inc.

NASDAQ:KRSAHealthcare · Medical - Pharmaceuticals

Mkt Cap$1.43B

Float2.37M

Shares O/S45.54M

Inst Own1.0%

SI0.5%

Dilution

-6.34%$31.31

AH Close$31.31+0.00%vs close

Mkt Cap$1.43B

Float2.37M

O/S45.54M

Inst Own1.0%

SI0.5%

Dilution

NASDAQ:KRSA$31.31-6.34%

MCap$1.43B

Float2.37M

O/S45.54M

SI0.5%

Inst Own1.0%

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap$1.43B

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership1.03%

based on 45.54M shares outstanding

SectorHealthcare

IndustryMedical - Pharmaceuticals

ExchangeNASDAQ

Country

IPO Date-

Shares Outstanding45.54M

Float2.37M

Company Overview

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics.

Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate.

The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Leadership

Regina Graul

Chief Executive Officer, President & Director

Mark Joseph Vignola

Chief Financial Officer

Rhonda Chicko

Chief Financial Officer

Gan Wei

Chief Technical Officer

Employees

Country

Sector

Healthcare

Website

korsana.com

Analyst Coverage

ConsensusBuy

Price Target (median, last 90d)

$55.00+75.7%

Low $43High $70

Ratings Distribution

BUY

HOLD

SELL

TOTAL2

Insider Trading

Insider	Title	Type	Shares	Value	Date
Pernice Michelle Patricia	Director	Grant/Award	48.4K	--	Sep 9, 2026
Shah Nimish P	Director	Grant/Award	48.4K	--	Sep 9, 2026
Fairmount Funds Management LLC	Director	Grant/Award	48.4K	--	Sep 9, 2026
Gottesdiener Andrew	Director	Grant/Award	48.4K	--	Sep 9, 2026

Shareholders

1.0%

Institutional

(21)

0.5%

Insiderⓘ

(4)

22.1%

5%+ Owners

(10)

of which 3.6% rests on schedules older than 24 months (1 holder)

76.3%

Unattributed (incl. retail)ⓘ

Institutional1.0%

Insider0.5%

5%+ Beneficial22.1%

Unattributed (incl. retail)76.3%

Top Shareholders

Name	Shares	%	Source
FMR LLC · net of 13F· joint filing· may incl. warrants· filed Oct 2026	3.1M	6.9%	13G
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. · may incl. warrants· filed Sep 2026	2.8M	6.1%	13G
Invus Public Equities, L.P. 2 · may incl. warrants· stale · filed Jul 2024	1.7M	3.6%	13G
Tomas Kiselak · joint filing· may incl. warrants· filed Sep 2026	1.3M	2.9%	13D
VHCP Co-Investment Holdings III, LLC · joint filing· may incl. warrants· filed Sep 2026	650.3K	1.4%	13D
GENERAL ATLANTIC, L.P. · joint filing· may incl. warrants· filed Sep 2026	457.3K	1.0%	13G
Kalehua Capital Management LLC	235.9K	0.5%	13F
Violin Jonathan See Remarks, Director	207.4K	0.5%	FORM 4
Peter M. Hecht · may incl. warrants· filed Jul 2026	130.0K	0.3%	13D
FMR LLC	92.8K	0.2%	13F